MONTREAL--(BUSINESS WIRE)--Feb. 13, 2006--ProMetic BioSciences Inc., the therapeutic unit of ProMetic Life Sciences Inc. (TSX:PLI.SV), announced today that it has received authorization from the Therapeutic Products Directorate of Health Canada to begin a Phase Ib/II clinical trial of PBI-1402, its novel therapeutic compound in development to treat patients with anemia.
